09:26 AM EDT, 06/20/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday it was planning to appeal against the UK's National Institute for Health and Care Excellence's, or NICE's, decision not to reimburse the cost of Alzheimer's drug Kisunla under the National Health Service.

The drugmaker said the regulator's decision is "unreasonable" based on the evidence submitted by the company, clinical experts and patient groups.

"This decision means that while patients can pay for the medicine privately, it will be denied to NHS patients in England," Eli Lilly ( LLY ) said.

The company said it remained confident in the clinical efficacy and cost-effectiveness of the drug.

NICE did not respond to MT Newswires' request for comment.

Lilly's shares edged 0.7% higher in recent premarket activity Friday.